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Summary
Most chemotherapeutic agents induce DNA damage, leading to p53 accumulation and apoptosis. The factors that determine
chemosensitivity in p53-defective tumor cells are poorly understood. We found that the p53 family member p73 is induced
by a wide variety of chemotherapeutic drugs. Blocking p73 function with a dominant-negative mutant, siRNA, or homologous
recombination led to chemoresistance of human tumor cells and engineered transformed cells, irrespective of p53 status.
Mutant p53 can inactivate p73 and downregulation of mutant p53 enhanced chemosensitivity. These findings indicate that
p73 is a determinant of chemotherapeutic efficacy in humans.
Introduction p73 responds to at least a subset of DNA-damaging drugs
(Agami et al., 1999; Costanzo et al., 2002; Gong et al., 1999;
Yuan et al., 1999). In the present report, we found that TAp73The tumor suppressor protein p53 plays a critical role in apopto-
sis induced by DNA-damaging agents, including many antican- is induced by a wide variety of chemotherapeutic agents and
that blocking TAp73 function leads to enhanced chemoresis-cer drugs (Johnstone et al., 2002; Ko and Prives, 1996). Unfortu-
nately, at least 50% of human cancers lack functional p53. The tance. Earlier studies showed that overproduction of certain
p53 mutants can (1) block chemotherapy-induced apoptosisp53 family members, p73 and p63, share significant sequence
homology with p53 but, unlike p53, give rise to multiple protein and (2) block p73 function (Blandino et al., 1999; Di Como et
al., 1999; Gaiddon et al., 2001; Li et al., 1998; Marin et al., 2000).isoforms due to alternative promoter utilization and alternative
mRNA splicing (Irwin and Kaelin, 2001; Melino et al., 2002). The Here we demonstrate that downregulation of endogenous mu-
tant p53 enhances chemosensitivity in p53-defective tumorTA isoforms of p63 and p73 (such as p73 and p73) contain
an N-terminal transactivation domain that is lacking in the corre- cells. Collectively, these results support a model wherein modu-
lation of chemosensitivity by mutant p53 is due, at least in part,sponding N isoforms. The TA isoforms can transactivate p53
target genes and induce apoptosis, whereas the N isoforms to perturbation of p73 function.
are dominant inhibitors of p53-responsive gene expression.
Therefore, p73 and p63 can have both proapoptotic and anti- Results
apoptotic effects. The antiapoptotic isoforms are predicted to
block the function of all three p53 family members (Ishimoto et We found that p73 and, to a lesser extent, p73, are induced
by a wide variety of chemotherapeutic agents in diverse tumoral., 2002; Pozniak et al., 2000; Stiewe et al., 2002; Zaika et al.,
2002). Accordingly, overproduction of antiapoptotic p73 iso- cell lines (Figure 1A and M.S.I. and W.G.K., unpublished data).
In some cases, p73 induction was only revealed after titrationforms can block chemotherapy-induced apoptosis in tumor
cells that retain wild-type p53 (Vossio et al., 2002; Zaika et al., experiments that examined the influence of drug dose and dura-
tion, perhaps accounting for the earlier conclusion that p73 was2002).
It was initially reported that p73 is not induced by DNA not responsive to DNA damage (Figure 1 and M.S.I. and W.G.K.,
unpublished data). For certain chemotherapeutic agents, p73damage (Kaghad et al., 1997). Subsequently, it was shown that
p73 is induced by cis-platinum and adriamycin, implying that induction was observed at low, but not high, drug concentra-
S I G N I F I C A N C E
p53 mediates DNA damage-induced apoptosis, but the efficacy of DNA-damaging chemotherapeutic agents is not restricted to
p53 (/) tumor cells. Moreover, p53 status cannot account for preferential killing of tumor cells by chemotherapeutic agents
relative to normal (p53/) cells. p73 is a p53 paralog that encodes proapoptotic (TA forms) and antiapoptotic (N forms) isoforms.
TAp73 levels are higher in tumor cells relative to normal cells and mutant p53 inhibits TAp73. We found that TA p73 is induced by
many chemotherapeutic agents and that inhibiting TA p73 increased chemoresistance. Conversely, downregulation of mutant p53
enhanced chemosensitivity. These results suggest that p73 contributes to chemotherapy-induced apoptosis and support a model
wherein mutant p53 induces chemoresistance, at least partly, through neutralization of p73.
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Figure 1. TA-p73 is induced by chemotherapy
A: Anti-p73 and anti-tubulin immunoblots of
SW480 cells treated for 24 hr with camptothecin
(0.3–1M), etoposide (VP-16) (0.5–5M), cisplati-
num (2–10 g/ml), doxorubicin (2–10 M), taxol
(25–100 nM), or DMSO (“-”) (0.1%). Similar results
were seen in HCT-116, T98G, and U20S cells (data
not shown).
B: Anti-p73 and anti-tubulin immunoblots of
SW480 cells treated with camptothecin (0.3 M)
for the indicated periods (hr).
tions (Figure 1A). The accumulation of p73 following chemother- not due to alterations in cell cycle distribution as determined by
fluorescence-activated cell sorting of propidium iodide-stainedapy treatment has been shown, when studied, to be due to
increased transcription and protein stabilization (Agami et al., cells (data not shown). Similar results were obtained with human
foreskin fibroblasts transformed in a similar manner to these1999; Chen et al., 2001; Costanzo et al., 2002; Gong et al.,
1999; Yuan et al., 1999). HEK cells (data not shown).
p73 DD blocks the function of both p73 and p63 (Irwin etTo ask whether accumulation of p73 contributes to chemo-
therapy-induced apoptosis, SW480 colon carcinoma cells were al., 2000). To more clearly define the role of TA-p73 in chemo-
therapy-induced apoptosis, double-stranded RNA oligonucleo-infected with recombinant adenoviruses encoding GFP and ei-
ther a dominant-negative p73 (p73DD) or a point mutant deriva- tides (siRNA) (Elbashir et al., 2001) homologous to 5 prime
unique TA-p73 sequences that are missing in Np73 were usedtive thereof [p73DD (L371P)]. p73DD, but not p73DD (L371P),
binds to p73 and prevents it from activating p53-responsive to inhibit the accumulation of p73 in tumor cells. Transfection
of p73 siRNA, but not unrelated or scrambled siRNA, led topromoters (Irwin et al., 2000). Likewise, p73DD, but not p73DD
(L371P), protected against etoposide (VP-16)-induced cell death decreased TA-p73 and TA-p73 in multiple cell lines without
affecting the levels of lamin or p53 (Figure 3A and data notas shown by an increase in adherent, viable appearing, GFP-
positive cells (Figure 2A). In contrast, no difference was ob- shown). p73 siRNA, but not control siRNAs, also inhibited the
accumulation of TA-p73 in response to DNA damage and con-served in untreated cells expressing either p73DD or p73DD
(L371P) (Figure 2A). ferred protection against a variety of chemotherapeutic agents
in both SW480 (p53R273H/p53P309S) colon cancer cells (IARCNext we sought to quantitate the effect of p73DD on chemo-
therapy-induced apoptosis in genetically defined transformed TP53 Database; Rodrigues et al., 1990) and U2OS (p53 wild-
type) osteosarcoma cells (Figures 3B, 4A and 4B, and data nothuman cells. Parallel cultures of primary human embryonic kid-
ney cells (HEK) transformed with the SV40 early region, H-Ras, shown). Notably, taxol did not increase p73 levels in SW480
cells under any condition tested (in contrast to U2OS cells)and the telomerase catalytic subunit (hTERT) were infected with
retroviruses encoding p73DD or p73DDL371P (Hahn et al., (Figure 1A and M.S.I. and W.G.K., unpublished data), and p73
siRNA did not protect SW480 cells from taxol-induced killing1999) (Figure 2B). The SV40 early region encodes large T anti-
gen, which inactivates both p53 and the retinoblastoma protein (Figure 4A). It is tempting to speculate that the more pronounced
effects of p73 siRNA in SW480 cells relative to U2OS cells is(pRB). After selection polyclonal, early passage cells were
treated with chemotherapeutic agents. Corroborating our previ- due to the fact that the former have mutant p53 and the latter
wild-type p53. However, a formal comparison between theseous results, expression of p73 DD inhibited chemotherapy-
induced apoptosis (Figures 2C and 2D). These effects were two cell lines is not possible because of many other, potentially
confounding, differences.specific as they were not observed in cells infected with a retrovi-
rus encoding p73DD L371P or with an empty virus and were Likewise, p73/ MEFs transformed with the SV40 large T
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Figure 2. Dominant-negative p73 inhibits chemotherapy-induced cell death
A: SW480 cells infected with a bicistronic adenoviral vector encoding GFP and p73DD (top) or GFP and p73DDL371P (bottom) were treated for 3 days
with etoposide (5 M) (right panel) or diluent only (right panel). Shown are representative fields.
B: Anti-T, anti-T7, and anti-Ras immunoblots of primary human kidney epithelial cells infected with retroviruses encoding SV40 early region, hTERT, and H-Ras
and then infected to produce T7 epitope-tagged p73DD or p73DD L371P.
C and D: Early passage (p4–8) transformed human kidney cells described in (B) were treated with camptothecin (1 M), etoposide (5 M), cisplatinum (2
g/ml), doxorubicin (2 M), or taxol (100 nM). XTT assays were performed 48 hr (C) and 72 hr (D) later in triplicate. Error bars equal one standard error.
antigen (T)  H-Ras were more resistant to chemotherapy- cells transfected with p73 siRNA. Chemotherapy-treated cells
transfected with p73 siRNA formed more colonies than cellsinduced killing than wild-type MEFs transformed with these
oncoproteins, although the effects were less dramatic than ob- transfected with buffer alone or scrambled p73 siRNA (Figure
4D). Importantly, neither the wild-type nor scrambled p73 siRNAserved with human tumor cell lines (Figure 4C). Whether this is
due to species or cell of origin differences is unknown. affected colony formation by untreated cells (data not shown).
Similarly, chemotherapy-treated HEK cells expressing p73DDLong-term viability assays often more accurately reflect the
in vivo chemosensitivity profiles of tumors (Brown and Wouters, formed more colonies than those expressing p73DDL371P (data
not shown).1999). Thus, we performed clonagenic assays using SW480
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siRNA, inhibited mutant p53 accumulation (Figure 6B) and, in
contrast to p73 siRNA, enhanced the effectiveness of chemo-
therapy (Figure 6C). This demonstrates that downmodulation
of endogenous, mutant p53 levels in a human tumor cell trans-
lates into increased cell killing by chemotherapeutic agents.
Similar results were obtained in C33A cervical carcinoma cells,
which also contain mutant p53 (Figure 6D and data not shown).
The effects in C33A cells were less striking than in SW480 cells,
however, which likely reflects the less efficient knockdown of
mutant p53 we achieved in these cells after siRNA treatment,
as determined by immunoblot analysis (data not shown).
Discussion
P53 plays a central role in the apoptotic response to DNA-
damaging agents. Nonetheless, the effectiveness of DNA-dam-
aging anticancer drugs is not restricted to tumors that retain
wild-type p53. Furthermore, the clinical utility of DNA-damaging
chemotherapeutic agents implies that normal tissues, which
retain wild-type p53, are less susceptible to apoptosis than
tumor cells, which typically lack functional p53. Our findings
shed light on these paradoxes by revealing a role for p73 in
chemotherapy-induced apoptosis. p73 is rarely mutated in can-
cer. Moreover, a variety of oncogenes activate p73, leading to
increased p73 levels in cancer cells relative to normal cells (Cai
et al., 2000; Irwin et al., 2000; Mai et al., 1998; Stiewe and
Putzer, 2000; Zaika et al., 1999; Zaika et al., 2001). A recent
study showed that the induction of apoptosis by p53 required
the presence of p73 (Flores et al., 2002). However, our findings
clearly show that p73 can induce apoptosis in tumor cells that
lack functional p53.
Figure 3. p73 siRNA inhibits TA-p73 induction by chemotherapy
Our findings, together with the knowledge that mutant p53
A: Anti-p73 and anti-tubulin immunoblots of SW480 cells transfected with can block p73 function, also provide a potential mechanistic
siRNA directed against TA-p73 (pairs p73-4, p73-3) or p53. In parallel, cells
basis for enhanced chemoresistance following experimentalwere transfected with annealing buffer only (mock) or scrambled p73 siRNA
overproduction of mutant p53 in tumor cells, including cells(p73-s).
B: Anti-p73 immunoblot of SW480 transfected as in (A). PGL3  luciferase lacking wild-type p53. Importantly, downregulation of endogenous
siRNA. 48 hr after transfection, cells were treated for 24 hr with DMSO or mutant p53 levels enhanced chemosensitivity, thereby supporting
camptothecin (300 nM). Similar results were seen after treatment with etopo-
a role for this phenomenon in nonmanipulated tumor cells. Addi-side (data not shown).
tional studies will be required to rigorously establish the degree
to which this enhanced chemosensitivity is due to p73.
The interaction of mutant p53 with p73 depends upon the
nature of the p53 mutation as well the status of codon 72 inAs expected, the increased viability of chemotherapy-
p53, which can encode Arg (R) or Pro (P) due to a commontreated cells transfected with p73 siRNA was due to a decreased
polymorphism in the human population (Marin et al., 2000). Inapoptosis. Caspase activation and TUNEL positivity were sig-
this regard, both the p53 alleles in SW480 cells encode for Argnificantly diminished in SW480 cells transfected with p73 siRNA
at codon 72 as determined by a PCR-based assay (data notrelative to cells transfected with control siRNA (Figures 5A–5C).
shown; Harris et al., 1986). p53 Arg72 mutants bind to p73 asThe experimental overproduction of certain “gain-of-func-
well or better than the corresponding Pro72 isoforms, perhapstion” p53 mutants, in both wild-type and p53 null tumor cells,
accounting for the preferential mutation and retention of the Rleads to increased chemoresistance (Blandino et al., 1999; Li
allele in tumors arising in R/P germline heterozygotes (Marin etet al., 1998). Likewise, some p53 mutants bind to and inactivate
al., 2000; Brooks et al., 2000; Soulitzis et al., 2002). In thep73 (Di Como et al., 1999; Gaiddon et al., 2001; Marin et al.,
accompanying manuscript, Crook and coworkers likewise re-2000, Bensaad et al., 2003). Our findings imply that these two
port that p53 Arg72 mutants are more potent inhibitors of che-phenomena might be linked. As anticipated, we detected mutant
motherapy-induced apoptosis than the corresponding Pro72p53 bound to p73 in SW480 cell extracts (Figure 6A). Note that
isoforms and provide evidence that p53 codon 72 status influ-since the former is in vast excess of the latter (Marin et al., 2000
ences clinical response to chemotherapy in man (Bergamaschiand data not shown), only a small fraction of the total pool of
et al., 2003 [this issue of Cancer Cell]).mutant p53 is bound to p73. On the other hand, when tested
Our results suggest that the response to chemotherapy isbefore in other cell types, the majority of p73 was bound to
influenced not only by p53, but instead by the status of a networkmutant p53 (Marin et al., 2000). To ask whether endogenous
that contains p53, p73, and perhaps the closely related proteinmutant p53 affects chemosensitivity, SW480 cells were treated
with p53 siRNA. Transfection of p53 siRNA, but not control p63. Therapeutic modulation of p73 and mutant p53 levels might
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Figure 4. Genetic disruption of TA-p73 enhances
chemoresistance
A and B: SW480 (A) and USOS (B) cells were trans-
fected with the indicated siRNAs and subse-
quently treated with campothecin (1 M), etop-
oside (5 M), cisplatinum (2 g/ml), doxorubicin
(2 M), or taxol (100 nM) for 72 hr prior to XTT
analysis. Similar results were seen at 48 hr (data
not shown).
C: Polyclonal populations of early passage
p73/ and p73/ MEFS transfected with plas-
mids encoding SV40 T antigen (T) and H-Ras were
treated with the indicated drugs for 72 hr prior
to XTT analysis.
D: SW480 cells transfected with p73 siRNA, an-
nealing buffer only, or scrambled p73 siRNA (p73-
s) were plated in triplicate into methylcellulose/
DMEM media containing doxorubicin, campto-
thecin, or diluent. The percentage of colonies
surviving in camptothecin (left) or doxorubicin
(right) relative to diluent alone is indicated.
T (Pab419; Harlow et al., 1981). Each lane contained comparable amounts ofbe used to target the large percentage of human tumors that
protein as determined by the Bradford Method.harbor p53 mutations. Intriguing in this regard are reports of
Immunoprecipitations were performed essentially as described by Marinsmall molecules that can induce mutant p53 to adopt a wild-
et al. (2000), using 1.5 mg of cell extract and either anti-p73 (mixture of ER-
type conformation (Bykov et al., 2002; Foster et al., 1999). Strat- 15 and ER-13), anti-p53 (mixture of PAb1801 and PAb 421), or control anti-T
egies to manipulate this network of proteins, including other (Pab419) monoclonal antibodies. ER-13 and ER-15 are specific for p73 and
do not crossreact with p53 (Marin et al., 2000). Bound p53 was detectedsmall molecules and adaptations of siRNA technology (McCaf-
by immunoblot assay with an anti-p53 (DO-1) primary antibody and a horse-frey et al., 2002), may thus prove useful in enhancing the re-
radish peroxidase (HRP)-conjugated secondary antibody against mouse im-sponse to traditional chemotherapeutic drugs or in overcoming
munoglobulin light chain (Pharmingen, clone 187.1).
chemoresistance in human cancers.
Generation of adenoviral plasmids
Experimental procedures Bicistronic adenoviral vectors (pAdCMV) encoding GFP and p73DD were
made using the AdEasy Vector System (Quantum Biotechnologies). The
Cell culture and chemotherapy treatment p73DD cDNAs from pcDNA3-T7-p73DD and pcDNA3-T7-p73DD (L371P)
SW480, U2OS, T98G, HCT-116, C33A human cancer cell lines and mouse (Irwin et al., 2000) were excised with HindIII and XbaI and ligated into pAD-
embryo fibroblasts (MEFs) were grown in DMEM supplemented with 10% Track-CMV cut with these two enzymes. The resulting plasmids were used
FBS at 37C in the presence of 10% CO2. Human kidney epithelial (HEK) cells to transform E. Coli strain BJ5183 in the presence of pAdEasy-1 to make
were grown in MEM-with 10% FBS. Camptothecin, etoposide, cisplatinum, pAd GFP-T7-p73DD and pAd GFP-T7-p73DD (L371P), respectively. Tissue
doxorubicin, and taxol were dissolved according to the manufacturer’s in- culture supernatants from QBI-293A cells transfected with pAd GFP-T7-
structions (Sigma) before addition to cell culture media. p73DD or pAd GFP-T7-p73DD (L371P) were harvested and viral particles
were purified by cesium chloride centrifugation. Equivalent amounts of infec-
Antibodies, western immunoblots, and immunoprecipitations tious particles were used to infect SW480 cells.
Immunoblot analysis was performed essentially as described before (Irwin et
al., 2000) with anti-p73 (ER-15; Marin et al., 2000), anti-p53 (DO-1, Oncogene Generation of HEK cell lines
Research), anti-Lamin (Cell Signaling Technology), anti-tubulin (clone B1.2.5, HEK cells were sequentially infected with retroviruses encoding the SV40
early region, hTERT, and G12V H-Ras as described before (Hahn et al.,Sigma), anti-Ras (C20, Santa Cruz Biotechnology), anti-T7 (Novagen), or anti-
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The PGL3 sequence has been previously described (Elbashir et al.,
2001). All siRNA sequences were subjected to BLAST search to confirm the
absence of homology to any additional known coding sequences in the
human genome. Oligonucleotides were deprotected and annealed according
to the manufacturer’s instructions (Dharmacon). Cells were transfected with
siRNA at approximately 20%–30% confluency using Oligofectamine (In-
vitrogen). The final concentration of siRNA was 30–100 nM, but was compa-
rable between each sample in a given experiment. For XTT assays, cells
were allowed to recover for 24 hr prior to transfer into 96-well plates. 24 hr
later, cells were treated with the indicated drugs. For TUNEL and caspase
activation assays, cells were allowed to recover for 48 hr prior to treatment
with chemotherapy.
XTT viability assays
XTT assays (sodium 3	–[1-(phenylamino-carbonyl)-3,4,-tetrazolium]-bis (4-meth-
oxy-6-nitro) benzene sulfonic acid hydrate) were performed in triplicate
according to the manufacturer’s instructions in 96-well plates (Roche) 24,
48, and 72 hr later. The colorimetric readout in this assay reflects the number
of metabolically active mitochondria, and hence viable cells, in a given well.
Values were normalized relative to cells not treated with chemotherapy. Data
shown are representative of three independent experiments.
Clonagenic assays
SW480 cells were transfected with siRNA as described above. 48 hr later,
2 
 104 cells were plated in triplicate in methylcellulose-DMEM media with
30% FCS containing DMSO, doxorubicin (0.02 M), or camptothecin (5 nM).
Surviving colonies were counted 10–14 days later.
Apoptosis assays
For caspase activation assays, siRNA-transfected cells were harvested at
the indicated time points following chemotherapy treatment and prepared
according to the manufacturer’s instructions (Caspase-3 Fluorometric and
Caspase-8 Fluorometric Assays, R&D Systems). One hundred microgramsFigure 5. Genetic disruption of TA-p73 inhibits chemotherapy-induced apo-
ptosis of each cell lysate was used in each reaction. Results were read using a
fluorescent plate reader at 400 nm (light excitation) and 505 nm (emission).A and B: SW480 cells transfected with the indicated siRNAs were treated
Caspase activation is expressed as fold increase relative to untreated cells.with camptothecin (1 M). Caspase-3 (A) and caspase 8 (B) activation
Data shown are representative of two independent experiments.assays were performed 20 and 36 hr later. Fold activation represents the
For TUNEL assays, cells were fixed in 4% paraformaldehyde at thecaspase activity measured in camptothecin-treated cells relative to mock-
treated cells harvested at the same time points. indicated times following chemotherapy treatment. Cells were prepared and
C: SW480 cells transfected with the indicated siRNAs were treated with stained according to the manufacturer’s instructions (In Situ Cell Death
increasing concentrations of camptothecin or DMSO ( 0 M). TUNEL stain- Detection Kit, Fluorescein, Roche). TUNEL-positive cells were detected by
ing was performed 48 hr later. Qualitatively similar results were obtained at flow cytometry. Data shown are representative of three independent experi-
36 hr (data not shown). ments.
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Figure 6. Downregulation of mutant p53 levels
enhances chemosensitivity
A: Extracts of SW480 cells treated with campto-
thecin (1M) (“”) or DMSO (“”) were immuno-
precipitated with anti-p73, anti-p53, or control
(anti-T) antibodies. Bound p53 was detected by
anti-p53 immunoblot analysis. Similar results were
obtained using SW480 cells treated with etopo-
side (data not shown).
B: Anti-p53 immunoblot of SW480 cells trans-
fected with siRNA directed against p53 (30 and
100 nM), luciferase (pGL3), or p73 (wild-type or
scrambled [s]).
C and D: SW480 (C) and C33A (D) cells were
transfected with the indicated siRNA oligonucle-
otides and subsequently treated with campo-
thecin (1M), cisplatinum (2g/ml), or doxorubi-
cin (2 M) for 72 hr prior to XTT analysis.
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